[go: up one dir, main page]

MA42641A1 - Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih - Google Patents

Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Info

Publication number
MA42641A1
MA42641A1 MA42641A MA42641A MA42641A1 MA 42641 A1 MA42641 A1 MA 42641A1 MA 42641 A MA42641 A MA 42641A MA 42641 A MA42641 A MA 42641A MA 42641 A1 MA42641 A1 MA 42641A1
Authority
MA
Morocco
Prior art keywords
trispecific
binding proteins
prevention
treatment
hiv infection
Prior art date
Application number
MA42641A
Other languages
English (en)
Inventor
Huawei Qiu
Christian Beil
Jochen Beninga
Christian Lange
Ercole Rao
Jochen Kruip
Zhi-Yong Yang
Gary Nabel
Ling Xu
Ronnie Wei
Wulf Leuschner
Mark Connors
John Mascola
Richard Koup
Jinghe Huang
Nicole Doria-Rose
Tongqing Zhou
Peter Kwong
Young Kwon
Amarendra Pegu
Mangaiarkarasi Asokan
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of MA42641A1 publication Critical patent/MA42641A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions comprenant des protéines de liaison trispecifiques et/ou trivalentes comprenant quatre chaînes polypeptidiques qui forment trois sites de liaison à l'antigène qui se lient spécifiquement à une ou plusieurs protéines cibles du vih ou un ou plusieurs récepteurs des lymphocytes t, une première paire de polypeptides qui forme la protéine de liaison possédant des domaines variables doubles ayant une orientation croisée et une seconde paire de polypeptides qui forme la prot
MA42641A 2016-02-24 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih MA42641A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305211 2016-02-24
PCT/US2016/058540 WO2017074878A1 (fr) 2015-10-25 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Publications (1)

Publication Number Publication Date
MA42641A1 true MA42641A1 (fr) 2019-03-29

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42641A MA42641A1 (fr) 2016-02-24 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Country Status (30)

Country Link
US (4) US20190054182A1 (fr)
EP (2) EP3819310A1 (fr)
JP (3) JP7169190B2 (fr)
KR (1) KR102687212B1 (fr)
CN (4) CN116789841A (fr)
AR (1) AR106466A1 (fr)
AU (2) AU2016347058B2 (fr)
BR (1) BR112018008011A2 (fr)
CA (1) CA3002664A1 (fr)
CL (1) CL2018001065A1 (fr)
CO (1) CO2018005337A2 (fr)
CR (1) CR20180288A (fr)
DO (1) DOP2018000102A (fr)
EA (1) EA201891028A1 (fr)
ES (1) ES2894304T3 (fr)
HR (1) HRP20211528T1 (fr)
HU (1) HUE056608T2 (fr)
IL (2) IL301140A (fr)
MA (1) MA42641A1 (fr)
MX (2) MX2018005048A (fr)
MY (1) MY192278A (fr)
PE (1) PE20181167A1 (fr)
PH (1) PH12018500873A1 (fr)
PL (1) PL3365366T3 (fr)
RS (1) RS62437B1 (fr)
SG (1) SG11201803324VA (fr)
SI (1) SI3365366T1 (fr)
TW (3) TW202442675A (fr)
UY (1) UY36965A (fr)
WO (1) WO2017074878A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052132B1 (fr) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
WO2019135921A1 (fr) * 2017-12-21 2019-07-11 Aaron Diamond Aids Research Center Anticorps bispécifiques neutralisants hiv-1
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
EP3110844B1 (fr) * 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps monoclonaux neutralisants à large spectre contre la région v1v2 env du vih-1
PE20181167A1 (es) * 2015-10-25 2018-07-19 Sanofi Sa Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
EP3371214A1 (fr) * 2015-11-03 2018-09-12 THE UNITED STATES OF AMERICA, represented by the S Anticorps neutralisants dirigés contre la protéine gp41 du vih-1 et leur utilisation
MX2018012566A (es) 2016-04-13 2019-08-05 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes.
FI3443006T3 (fi) * 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
EP3448987A4 (fr) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018151841A1 (fr) 2017-02-17 2018-08-23 Sanofi Molécules de liaison multispécifiques ayant une spécificité vis-à-vis du dystroglycane et de la laminine-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
BR112019020235A2 (pt) * 2017-03-27 2020-04-22 The Wistar Institute Of Anatomy And Biology molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
AU2018290228B2 (en) * 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
JP7036909B2 (ja) * 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
WO2019123262A1 (fr) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Polypeptides de liaison à un antigène
KR102737364B1 (ko) 2018-01-12 2024-12-05 젠자임 코포레이션 폴리펩티드의 정량화를 위한 방법
WO2019226829A1 (fr) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
MX2021004147A (es) * 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
WO2020106713A1 (fr) * 2018-11-21 2020-05-28 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
MY208876A (en) * 2019-04-09 2025-06-05 Sanofi Sa Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
CN116157416A (zh) * 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法
AU2022354068A1 (en) * 2021-09-29 2024-04-18 Modex Therapeutics, Inc. Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN118660907A (zh) * 2021-09-29 2024-09-17 摩德斯医疗股份有限公司 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2025108551A1 (fr) 2023-11-23 2025-05-30 Mabylon Ag Anticorps anti-allergènes multispécifiques et leurs utilisations
WO2025109206A1 (fr) 2023-11-22 2025-05-30 Mabylon Ag Anticorps anti-allergènes multispécifiques et leurs utilisations
US20250376537A1 (en) 2024-05-17 2025-12-11 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
EP1641827A2 (fr) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Molecules de liaison modifiees comprenant des peptides de connexion
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (fr) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2774636C (fr) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre le vih-1 et utilisation associee
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
EP2638072A4 (fr) 2010-11-12 2014-05-07 Univ Rockefeller Protéines de fusion pour une thérapie contre le vih
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (fr) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisants anti-vih-1 et leur utilisation
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
DK2710033T3 (da) * 2011-05-17 2021-03-08 Univ Rockefeller Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf
US9475862B2 (en) 2011-11-07 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing GP41 antibodies and their use
EP2776061B1 (fr) * 2011-11-07 2019-08-14 MedImmune, LLC Protéines de liaison multispécifiques et multivalentes et leurs utilisations
EP2788376B1 (fr) 2011-12-08 2018-10-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps neutralisants dirigés contre le vih-1 et leur utilisation
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP3401337A1 (fr) * 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification d'immunoglobulines hétérodimères
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
NZ708182A (en) * 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP2016517277A (ja) 2013-03-15 2016-06-16 アッヴィ・インコーポレイテッド ＴＮＦαに対して指向された二重特異的結合タンパク質
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3027755B1 (fr) 2013-08-02 2019-10-09 The Regents of The University of California Modification d'une immunité antivirale médiée par les cellules t par des cellules souches et des récepteurs d'antigène chimériques
NZ720161A (en) 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
KR102680151B1 (ko) 2015-01-23 2024-07-03 사노피 항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
CA2986237A1 (fr) 2015-05-20 2016-11-24 Quantum-Si Incorporated Procede de determination de la sequence d'un acide nucleique au moyen dela luminescence a resolution temporelle
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
EA201890782A1 (ru) 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv
PE20181167A1 (es) 2015-10-25 2018-07-19 Sanofi Sa Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
EA202091898A1 (ru) 2015-12-15 2021-06-22 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
MX2018012566A (es) 2016-04-13 2019-08-05 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes.
FI3443006T3 (fi) 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
EP3575319A4 (fr) 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. Molécule bifonctionnelle et son utilisation
WO2018151841A1 (fr) 2017-02-17 2018-08-23 Sanofi Molécules de liaison multispécifiques ayant une spécificité vis-à-vis du dystroglycane et de la laminine-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
BR112019020235A2 (pt) 2017-03-27 2020-04-22 The Wistar Institute Of Anatomy And Biology molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
US20250312475A1 (en) 2025-10-09
IL301140A (en) 2023-05-01
NZ781602A (en) 2025-07-25
MY192278A (en) 2022-08-16
PE20181167A1 (es) 2018-07-19
EP3365366A1 (fr) 2018-08-29
JP2023085476A (ja) 2023-06-20
EA201891028A1 (ru) 2019-02-28
ES2894304T3 (es) 2022-02-14
BR112018008011A2 (en) 2018-10-30
JP2021072847A (ja) 2021-05-13
WO2017074878A8 (fr) 2018-05-24
AU2016347058B2 (en) 2023-11-09
AR106466A1 (es) 2018-01-17
CN116789841A (zh) 2023-09-22
NZ742825A (en) 2024-04-26
CN116675776A (zh) 2023-09-01
IL258822A (en) 2018-06-28
MX2022014631A (es) 2023-01-11
TW201730210A (zh) 2017-09-01
UY36965A (es) 2017-05-31
TW202442675A (zh) 2024-11-01
HRP20211528T1 (hr) 2021-12-24
PH12018500873A1 (en) 2018-11-12
US20190054182A1 (en) 2019-02-21
IL258822B2 (en) 2023-08-01
JP7328267B2 (ja) 2023-08-16
CA3002664A1 (fr) 2017-05-04
US20220226495A1 (en) 2022-07-21
JP7724814B2 (ja) 2025-08-18
US20200054765A1 (en) 2020-02-20
HUE056608T2 (hu) 2022-02-28
CL2018001065A1 (es) 2018-11-23
HK1253385A1 (zh) 2019-06-14
IL258822B1 (en) 2023-04-01
AU2016347058A1 (en) 2018-06-14
CO2018005337A2 (es) 2018-07-10
US11129905B2 (en) 2021-09-28
SG11201803324VA (en) 2018-05-30
KR102687212B1 (ko) 2024-07-19
EP3365366B1 (fr) 2021-07-14
CN109311966A (zh) 2019-02-05
EP3819310A1 (fr) 2021-05-12
WO2017074878A1 (fr) 2017-05-04
TW202219064A (zh) 2022-05-16
JP2018537966A (ja) 2018-12-27
US11779651B2 (en) 2023-10-10
MX2018005048A (es) 2018-09-06
CR20180288A (es) 2018-09-11
TWI750139B (zh) 2021-12-21
PL3365366T3 (pl) 2022-01-31
CN117069855A (zh) 2023-11-17
JP7169190B2 (ja) 2022-11-10
CN109311966B (zh) 2023-03-10
RS62437B1 (sr) 2021-11-30
KR20180063336A (ko) 2018-06-11
DOP2018000102A (es) 2018-11-30
SI3365366T1 (sl) 2022-02-28
AU2024200395A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MA42641A1 (fr) Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih
MA44670B1 (fr) Protéines de liaison trispécifiques et/ou trivalentes
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MA35051B1 (fr) Protéines de liaison à des anticorps-like à double région variable ayant une orientation croisée de région de liaison
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
EP3883602A4 (fr) Antigènes peptidiques de la protéine tau et anticorps se liant à ceux-ci pour le traitement des tauopathies
PH12022551231A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
MX2021012386A (es) Proteínas de union triespecíficas, métodos y usos de las mismas.
MA39342B2 (fr) Anticorps il -21
MA38161A1 (fr) Anticorps anti-bmp-6
EP3930852A4 (fr) Protéines de liaison à l'antigène se liant à bcma
EP3932936A4 (fr) Polypeptide ayant une activité antibactérienne, composition pour la prévention ou le traitement de la septicémie comprenant celui-ci, et composition antibactérienne
Zhang et al. Cyclase-associated protein 1 (CAP1) is a prenyl-binding partner of Rap1 GTPase
MA55609A (fr) Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih
MA61946B1 (fr) Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
EA202092229A1 (ru) Мутеины cd4 и способы их применения
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
EP4048288A4 (fr) Agent anti-c5 pour le traitement de la dégénérescence maculaire liée à l'âge (dmla) sèche ou d'une atrophie géographique secondaire à la dmla sèche
EP3808842A4 (fr) Composition pharmaceutique pour le traitement d'une immunodéficience complexe sévère comprenant une protéine de fusion d'un peptide de pénétration cellulaire et de l'adénosine désaminase
EP3999187A4 (fr) Lymphocytes t à longue durée de vie pour le traitement d'une infection par le vih
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EA202190836A1 (ru) Антитела и антигенсвязывающие фрагменты против гликопротеина шипов sars-cov-2
MX2018016413A (es) Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.